Myriad Genetics Said Due To Significant Disparities Between GeneSight Group And Control Group, Myriad Concluded That The Control Group Was Not Viable, Leading To The Discontinuation Of The Second Part Of The Study
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics has decided to discontinue the second part of a study due to significant disparities between the GeneSight group and the control group, which was deemed not viable.
September 04, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Myriad Genetics has discontinued the second part of a study involving GeneSight due to significant disparities with the control group, which was not viable.
The discontinuation of the study could raise concerns about the viability and effectiveness of GeneSight, potentially affecting investor confidence. However, the direct impact on stock price is uncertain without further context on the study's significance to Myriad's overall business.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100